Welcome to our dedicated page for Pacific Biosc SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, annual and quarterly reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on PacBio’s financial performance, risk factors, and business operations related to its advanced sequencing solutions and integrated genetic analysis platforms.
For a life science technology company like PacBio, investors often look to annual reports on Form 10-K and quarterly reports on Form 10-Q for discussions of revenue from instruments, consumables, and services, as well as commentary on product adoption, research collaborations, and regional trends. Current reports on Form 8-K, such as the November 5, 2025 filing that furnished a press release on third quarter 2025 financial results, provide timely updates on material events and earnings announcements.
Stock Titan enhances these SEC filings with AI-powered summaries designed to explain key sections in clear language. Instead of reading full-length documents unaided, users can rely on AI-generated highlights to understand topics such as PacBio’s use of GAAP and non-GAAP financial measures, its description of sequencing platforms and applications, and management’s discussion of business risks and opportunities.
In addition to periodic reports and 8-Ks, investors may also review proxy statements and, where applicable, insider transaction reports on Form 4 to understand equity-related activity by officers and directors. With real-time updates from EDGAR and AI-assisted insights, this PACB filings page helps users quickly locate and interpret the regulatory information that PacBio provides about its operations in genomic sequencing and analytical laboratory instruments.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Michele Farmer reported two open-market sales of common stock that were mandatorily executed to cover tax withholding on vesting restricted stock units. On February 17, 2026, Farmer sold 35,215 shares at a weighted average price of $1.576 per share. On February 18, 2026, Farmer sold 14,952 shares at a weighted average price of $1.629 per share, reflecting sale price ranges disclosed in the footnotes. After these tax-related sales, Farmer directly owned 219,092 shares of PACB common stock.
An investor in PACB filed a Rule 144 notice covering the planned sale of 303,739 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on 02/17/2026 on the NASDAQ market.
The filing lists an aggregate market value of 478,692.66 for the shares to be sold and notes that 301,907,431 shares of this class were outstanding. The seller acquired these shares as restricted stock from the issuer on 02/15/2026, with no special payment terms disclosed.
A PACB shareholder filed a notice to sell 606,312 common shares under Rule 144. The planned sale through Morgan Stanley Smith Barney LLC has an aggregate market value of $955,547.71 and is targeted around 02/17/2026 on the NASDAQ exchange.
The shares were acquired as restricted stock from the issuer on 02/15/2026. The notice states that the seller does not know of any undisclosed material adverse information about PACB’s current or prospective operations. PACB had 301,907,431 shares outstanding at the time referenced.
Pacific Biosciences of California, Inc. reported mixed fourth-quarter and full-year 2025 results, combining solid revenue growth with large GAAP losses driven by restructuring and non-cash charges. Q4 2025 revenue rose to $44.6 million from $39.2 million, with full-year 2025 revenue edging up to $160.0 million from $154.0 million. Consumables were a key driver, reaching $21.6 million in Q4 and $82.0 million for 2025, while instrument revenue declined year over year on a full-year basis.
Non-GAAP gross margin improved to 40% for both Q4 and 2025, up from 31% and 33% in the prior-year periods, reflecting better underlying profitability. Yet GAAP net loss widened to $546.4 million for 2025 from $309.9 million, largely due to restructuring, impairment, amortization and the absence of a prior-year $154.4 million debt restructuring gain. Non-GAAP net loss improved to $158.8 million from $228.0 million, and year-end cash, cash equivalents and investments were $279.5 million. The company also completed the sale of short-read sequencing assets for net proceeds of about $48.1 million and highlighted collaborations and product innovations aimed at long-read sequencing growth.
Pacific Biosciences of California, Inc. reported an internal, interim reassignment of executive responsibilities. Effective January 28, 2026, Chief Operating Officer Mark Van Oene now oversees the company’s sales and customer support teams, duties that were previously handled by President and Chief Executive Officer Christian Henry.
At the same time, Mr. Henry has temporarily taken over responsibility for operations and research and development, which had been under Mr. Van Oene. Both executives keep their existing roles and core duties, and the company states there will be no changes to their titles or compensation in connection with this shift.
ARK Investment Management LLC and Catherine D. Wood report significant ownership in Pacific Biosciences of California, Inc. They disclose beneficial ownership of 37,264,228 shares of the company’s common stock, representing 12.34% of the class, based on an event date of December 31, 2025. ARK has sole voting power over 34,971,286 shares and shared voting power over 620,864 shares, while Wood has shared voting power over 35,592,150 shares. Both certify the holdings were acquired and are held in the ordinary course of business, not for changing or influencing control. ARK Innovation ETF is noted as a client with an interest exceeding 5%.
Pacific Biosciences of California, Inc. completed an asset sale to Illumina Cambridge Limited, transferring intellectual property and other assets tied to its short-read DNA sequencing and related reagent and detection technologies. The buyer paid $50.0 million in cash and assumed certain liabilities.
PacBio also received a non-exclusive license back to some of the sold intellectual property, allowing continued access to those technologies. At PacBio’s direction, the buyer will pay 4% of the net proceeds from the purchase price to former Apton Biosystems equity holders in connection with waived milestones, leaving PacBio with approximately $48.1 million in net cash proceeds from the transaction.
Pacific Biosciences of California, Inc. filed a current report to highlight a business update and unaudited preliminary financial results for the quarter and year ended December 31, 2025. The company issued a press release that includes preliminary revenue estimates and a preliminary balance of cash, cash equivalents and investments as of December 31, 2025.
Portions of the press release that cover these preliminary figures and the forward-looking statements section are treated as filed under the "Other Events" section, while the broader business update and results discussion are furnished under results-of-operations disclosure rules. The company notes that its financial statements for this period are not yet finalized or audited and may change materially, and cautions readers not to place undue reliance on the preliminary information.
Pacific Biosciences (PACB) filed its quarterly report, highlighting restructuring impacts and continued losses. Q3 revenue was $38.4 million versus $40.0 million a year ago, while gross profit improved to $15.9 million. Operating loss narrowed to $38.9 million from $64.1 million as cost of revenue declined.
Year to date, the company recorded a net loss of $506.0 million, driven primarily by $359.3 million of accelerated amortization tied to discontinued short-read development and a $15.0 million IPR&D impairment. Stockholders’ equity fell to $36.1 million from $506.6 million at year-end. Cash and investments totaled $298.7 million as of September 30, including $56.5 million in cash. Operating cash outflow was $92.1 million for the nine months. Convertible notes totaled $645.2 million (net), including the 2029 and 2030 notes; contingent consideration from the Apton deal was reduced to $0. Shares outstanding were 301,907,431 as of October 31, 2025.
Pacific Biosciences of California, Inc. reported that it announced financial results for its third fiscal quarter ended September 30, 2025. The company disclosed that these third-quarter 2025 results, covering its results of operations and financial condition, are presented in a press release titled “PacBio Announces Third Quarter 2025 Financial Results.”
The press release is furnished as Exhibit 99.1 to this report, meaning it provides the detailed quarterly figures and commentary, while the report itself primarily serves to formally notify investors that the results have been released.